Incyte upgraded to Buy from Neutral at Lazard Capital
Lazard Capital upgraded Incyte with a $25 price target citing increased penetration estimates for Jakafi in myelofibrosi.
Good morning EJ,
Thanks for posting...I guess Lazard finally gets the value of Jakafi and our pipeline...
Have a great day!